Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease - authors' reply

Aliment Pharmacol Ther. 2015 Oct;42(7):940-1. doi: 10.1111/apt.13368.

Authors

M Chaparro¹, J P Gisbert²

Affiliations

¹ Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. [email protected].
² Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.

PMID: 26331561
DOI: 10.1111/apt.13368

No abstract available

Publication types

Letter
Comment

MeSH terms

Colitis, Ulcerative / drug therapy*
Crohn Disease / drug therapy*
Humans
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Tumor Necrosis Factor-alpha